AMOT is required for YAP function in high glucose induced liver malignancy

Area of Science:

• Cell Biology
• Molecular Biology
• Biochemistry

Background:

• The interaction between AMOT and YAP is known, but its regulatory mechanism remains unclear.
• The Hippo signaling pathway is crucial in organ size control and cancer development.
• Aberrant Hippo pathway signaling is implicated in liver cancer, particularly in the context of diabetes.

Purpose of the Study:

• To investigate the role of AMOT in regulating YAP.
• To explore the impact of high glucose on AMOT expression and function.
• To elucidate the therapeutic potential of targeting AMOT and YAP in diabetes-associated liver cancer.

Main Methods:

• O-GlcNAcylation assays to detect post-translational modification of AMOT.
• Western blotting and qPCR to measure AMOT and YAP expression.
• Cellular localization studies to assess nuclear accumulation of YAP.
• Animal models (STZ-induced diabetic mice) to study in vivo effects.

Main Results:

• AMOT, a Hippo pathway core factor, undergoes O-GlcNAcylation, which is enhanced by high glucose.
• High glucose stimulates AMOT-mediated nuclear accumulation, transcriptional activity, and target gene transcription of YAP.
• AMOT acts as a YAP suppressor under normal glucose conditions but as a stimulator in high glucose.
• Upregulation and nuclear accumulation of AMOT and YAP were observed in high glucose mice.

Conclusions:

• AMOT acts as a YAP stimulator under high glucose conditions, contrasting its role at normal glucose levels.
• Targeting aberrantly regulated Hippo pathway core factors like AMOT and YAP presents a potential therapeutic strategy for liver cancer associated with diabetes.